Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
6772 | 1445 | 30.1 | 63% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
5 | 4 | CHEMISTRY, ORGANIC//CHEMISTRY, INORGANIC & NUCLEAR//CHEMISTRY, MULTIDISCIPLINARY | 1745167 |
346 | 3 | CARDIOTOXICITY//ANTHRACYCLINES//CAMPTOTHECIN | 36072 |
2496 | 2 | IFOSFAMIDE//CHEMOSENSITIVITY TEST//MESNA | 3914 |
6772 | 1 | IFOSFAMIDE//MESNA//TROFOSFAMIDE | 1445 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | IFOSFAMIDE | authKW | 1615886 | 19% | 28% | 269 |
2 | MESNA | authKW | 559028 | 4% | 42% | 63 |
3 | TROFOSFAMIDE | authKW | 432835 | 2% | 79% | 26 |
4 | BNP7787 | authKW | 338081 | 1% | 100% | 16 |
5 | OXAZAPHOSPHORINES | authKW | 327718 | 2% | 57% | 27 |
6 | CHLOROACETALDEHYDE | authKW | 317300 | 2% | 52% | 29 |
7 | GLUFOSFAMIDE | authKW | 300513 | 1% | 89% | 16 |
8 | ISOPHOSPHORAMIDE MUSTARD | authKW | 192090 | 1% | 91% | 10 |
9 | 4 HYDROXYCYCLOPHOSPHAMIDE | authKW | 178977 | 1% | 71% | 12 |
10 | DIMESNA | authKW | 147910 | 0% | 100% | 7 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Oncology | 10140 | 44% | 0% | 630 |
2 | Pharmacology & Pharmacy | 5432 | 37% | 0% | 529 |
3 | Chemistry, Medicinal | 807 | 8% | 0% | 111 |
4 | Chemistry, Analytical | 429 | 9% | 0% | 127 |
5 | Toxicology | 308 | 5% | 0% | 74 |
6 | Pediatrics | 244 | 5% | 0% | 79 |
7 | Biochemical Research Methods | 184 | 5% | 0% | 68 |
8 | Hematology | 145 | 4% | 0% | 56 |
9 | Urology & Nephrology | 83 | 3% | 0% | 43 |
10 | Medical Laboratory Technology | 44 | 1% | 0% | 17 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | NIOMECH | 63390 | 0% | 100% | 3 |
2 | CIHR GSK CHAIR PAEDIAT CLIN PHARMACOL | 48017 | 0% | 45% | 5 |
3 | CLIN PHARMACOL BIOANAL | 47541 | 0% | 75% | 3 |
4 | KRIGO | 47541 | 0% | 75% | 3 |
5 | CLIN PHARMACOL TOXICOL PHARMACOKINET | 42260 | 0% | 100% | 2 |
6 | METAB MALAD METAB U820 | 28172 | 0% | 67% | 2 |
7 | SLOTERVAART HOSP | 23372 | 1% | 8% | 14 |
8 | ALLOGENE STEM CELL TRANSPLANTA | 21130 | 0% | 100% | 1 |
9 | BRADFORT NHS TRUST BEATSON ONCOL | 21130 | 0% | 100% | 1 |
10 | CANC 441 KOMATSUSHIMA AOBA KU | 21130 | 0% | 100% | 1 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | CANCER CHEMOTHERAPY AND PHARMACOLOGY | 38710 | 8% | 2% | 116 |
2 | SEMINARS IN ONCOLOGY | 4644 | 2% | 1% | 34 |
3 | CANCER TREATMENT REVIEWS | 4319 | 1% | 1% | 20 |
4 | ANTI-CANCER DRUGS | 3692 | 2% | 1% | 24 |
5 | NORTH DAKOTA COOPERATIVE EXTENSION SERVICE CIRCULAR | 3520 | 0% | 17% | 1 |
6 | DRUG METABOLISM AND DISPOSITION | 3203 | 2% | 0% | 34 |
7 | JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY | 3164 | 2% | 1% | 27 |
8 | INVESTIGATIONAL NEW DRUGS | 2957 | 1% | 1% | 19 |
9 | MEDICAL AND PEDIATRIC ONCOLOGY | 2709 | 1% | 1% | 18 |
10 | CANCER TREATMENT REPORTS | 2131 | 1% | 1% | 15 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | IFOSFAMIDE | 1615886 | 19% | 28% | 269 | Search IFOSFAMIDE | Search IFOSFAMIDE |
2 | MESNA | 559028 | 4% | 42% | 63 | Search MESNA | Search MESNA |
3 | TROFOSFAMIDE | 432835 | 2% | 79% | 26 | Search TROFOSFAMIDE | Search TROFOSFAMIDE |
4 | BNP7787 | 338081 | 1% | 100% | 16 | Search BNP7787 | Search BNP7787 |
5 | OXAZAPHOSPHORINES | 327718 | 2% | 57% | 27 | Search OXAZAPHOSPHORINES | Search OXAZAPHOSPHORINES |
6 | CHLOROACETALDEHYDE | 317300 | 2% | 52% | 29 | Search CHLOROACETALDEHYDE | Search CHLOROACETALDEHYDE |
7 | GLUFOSFAMIDE | 300513 | 1% | 89% | 16 | Search GLUFOSFAMIDE | Search GLUFOSFAMIDE |
8 | ISOPHOSPHORAMIDE MUSTARD | 192090 | 1% | 91% | 10 | Search ISOPHOSPHORAMIDE+MUSTARD | Search ISOPHOSPHORAMIDE+MUSTARD |
9 | 4 HYDROXYCYCLOPHOSPHAMIDE | 178977 | 1% | 71% | 12 | Search 4+HYDROXYCYCLOPHOSPHAMIDE | Search 4+HYDROXYCYCLOPHOSPHAMIDE |
10 | DIMESNA | 147910 | 0% | 100% | 7 | Search DIMESNA | Search DIMESNA |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | KERBUSCH, T , DE KRAKER, J , KEIZER, HJ , VAN PUTTEN, JWG , GROEN, HJM , JANSEN, RLH , SCHELLENS, JHM , BEIJNEN, JH , (2001) CLINICAL PHARMACOKINETICS AND PHARMACODYNAMICS OF IFOSFAMIDE AND ITS METABOLITES.CLINICAL PHARMACOKINETICS. VOL. 40. ISSUE 1. P. 41 -62 | 132 | 81% | 62 |
2 | GIRAUD, B , HEBERT, G , DEROUSSENT, A , VEAL, GJ , VASSAL, G , PACI, A , (2010) OXAZAPHOSPHORINES: NEW THERAPEUTIC STRATEGIES FOR AN OLD CLASS OF DRUGS.EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY. VOL. 6. ISSUE 8. P. 919 -938 | 96 | 73% | 24 |
3 | ZHANG, J , TIAN, Q , CHAN, SY , LI, SC , ZHOU, SF , DUAN, W , ZHU, YZ , (2005) METABOLISM AND TRANSPORT OF OXAZAPHOSPHORINES AND THE CLINICAL IMPLICATIONS.DRUG METABOLISM REVIEWS. VOL. 37. ISSUE 4. P. 611 -703 | 196 | 36% | 95 |
4 | DE JONGE, ME , HUITEMA, ADR , RODENHUIS, S , BEIJNEN, JH , (2005) CLINICAL PHARMACOKINETICS OF CYCLOPHOSPHAMIDE.CLINICAL PHARMACOKINETICS. VOL. 44. ISSUE 11. P. 1135-1164 | 104 | 64% | 116 |
5 | BAUMANN, F , PREISS, R , (2001) CYCLOPHOSPHAMIDE AND RELATED ANTICANCER DRUGS.JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES. VOL. 764. ISSUE 1-2. P. 173 -192 | 93 | 73% | 57 |
6 | WAGNER, T , (1994) IFOSFAMIDE CLINICAL PHARMACOKINETICS.CLINICAL PHARMACOKINETICS. VOL. 26. ISSUE 6. P. 439-456 | 77 | 88% | 69 |
7 | BODDY, AV , YULE, SM , (2000) METABOLISM AND PHARMACOKINETICS OF OXAZAPHOSPHORINES.CLINICAL PHARMACOKINETICS. VOL. 38. ISSUE 4. P. 291 -304 | 72 | 67% | 105 |
8 | ZHANG, J , TIAN, Q , ZHU, YZ , XU, AL , ZHOU, SF , (2006) REVERSAL OF RESISTANCE TO OXAZAPHOSPHORINES.CURRENT CANCER DRUG TARGETS. VOL. 6. ISSUE 5. P. 385-407 | 112 | 41% | 6 |
9 | HANLY, L , CHEN, N , RIEDER, M , KOREN, G , (2009) IFOSFAMIDE NEPHROTOXICITY IN CHILDREN: A MECHANISTIC BASE FOR PHARMACOLOGICAL PREVENTION.EXPERT OPINION ON DRUG SAFETY. VOL. 8. ISSUE 2. P. 155-168 | 59 | 68% | 15 |
10 | AJITHKUMAR, T , PARKINSON, C , SHAMSHAD, F , MURRAY, P , (2007) IFOSFAMIDE ENCEPHALOPATHY.CLINICAL ONCOLOGY. VOL. 19. ISSUE 2. P. 108-114 | 41 | 95% | 32 |
Classes with closest relation at Level 1 |